Mass Tort Data Intelligence
Real-time docket tracking, filing velocity, and litigation intelligence across 50 active mass tort dockets.
Bard PowerPort Defense Verdict — First Bellwether Loss Threatens 3,044-Case MDL
A federal jury delivered a complete defense verdict in the first Bard PowerPort bellwether trial on May 11, 2026, dealing a significant blow to the 3,044-case MDL 3081. The outcome shifts settlement leverage heavily toward Becton Dickinson (NYSE: BDX, ~$69B market cap), which now faces minimal immediate pressure to resolve claims alleging catheter fractures and migration injuries. Plaintiff firms must reassess trial strategy before the next bellwether, while BDX may resist global resolution absent adverse rulings. The MDL had been among the fastest-growing device litigations, but this verdict introduces meaningful downside risk to plaintiff case values and could slow new filing velocity.
Defendant Market Impact
Verdict Breakdown
MDL 3081 Concurrent Proceedings
Key Developments
Jury found no design defect or failure to warn in first PowerPort injury case after bellwether trial concluded May 11
MDL 3081 contains 3,044 cases alleging catheter fracture, migration, and perforation injuries from Bard PowerPort devices
Defense verdict shifts settlement dynamics heavily in favor of Becton Dickinson, removing urgency for global MDL resolution
PowerPort litigation had been among fastest-growing device MDLs (trend: FAST per provided data), but filing momentum may decelerate post-verdict
Plaintiff leadership must reposition trial strategy and case selection before second bellwether to preserve MDL viability
Plaintiff Firm Rankings — May 26 – Jun 8, 2026
| # | Firm | City | Active Dockets | New | Leadership Status |
|---|---|---|---|---|---|
| 1 | Motley Rice LLC | Mt. Pleasant, SC | Social Media, AFFF, Talc | 45 | PSC — MDL 3047, MDL 2873 |
| 2 | Levin Papantonio Rafferty | Pensacola, FL | AFFF, Hair Relaxer, PowerPort | 38 | Co-Lead — MDL 2873 |
| 3 | Beasley Allen | Montgomery, AL | Paragard, Ozempic, Hair Relaxer | 32 | PSC — MDL 3094, MDL 2750 |
| 4 | Seeger Weiss LLP | New York, NY | Acetaminophen, FreeStyle Libre, Social Media | 30 | Co-Lead — MDL 3043 |
| 5 | Wisner Baum | Los Angeles, CA | Acetaminophen, Depo-Provera, Social Media | 28 | PSC — MDL 3043, MDL 3140 |
| 6 | Slater Slater Schulman | New York, NY | Uber, Lyft, Social Media | 25 | Lead — MDL 3084 |
| 7 | TorHoerman Law | Edwardsville, IL | Hair Relaxer, Paragard, Social Media | 22 | PSC — MDL 3060 |
| 8 | Weitz & Luxenberg | New York, NY | FreeStyle Libre, 1,4-Dioxane, Talc | 20 | PSC — MDL 2738 |
MDL Case Count Tracker — May 26 – Jun 8, 2026
50 dockets| Tort | MDL # | Total | New (Wk) | Trend | Key Development |
|---|---|---|---|---|---|
Tech | Pre-MDL | ~500+ | ~35 | FAST | State AG actions accelerating. Epic Games $520M FTC precedent. MDL formation expected 2026. |
Tech | 3047 | 10,000+ | ~30 | ACTIVE | Post-verdict momentum. Meta/Google appeal expected. Federal bellwether Jun 15 on track. |
Talc / J&JBorderline Consumer | 2738 | 67,200+ | ~45 | FILING | CA $950M verdict vacated Mar 17. Continued high-volume filing. |
Hair RelaxerOpen Consumer | 3060 | ~15,100 | ~25 | ACTIVE | BELLWETHER SELECTION: Judge Rowland selected 3 cases Apr 1. |
Chemical | 2873 | 15,250+ | ~40 | FILING | Steady high-volume intake. Motley Rice, Levin Papantonio active. |
Device | 2846 | 23,800+ | ~50 | FILING | Continued largest filing volume. |
Depo-ProveraOpen Pharma | 3140 | 3,490+ | ~40 | FAST | Expert deps completed Mar 20. Preemption motion under advisement. |
Pharma | 3092 | ~8,500 | ~5 | FLAT | Bellwether discovery continues. |
Ozempic / GLP-1Open Pharma | 3094 | 3,546+ | ~20 | ACTIVE | Entering critical Daubert/SJ phase. |
Bard PowerPortOpen Device | 3081 | 3,044+ | ~40 | ACTIVE | TRIAL IMMINENT: Cook bellwether Apr 21. |
Paragard IUDBorderline Device | 2750 | 3,600+ | ~25 | FILING | Beasley Allen, TorHoerman active. Mediation ongoing. |
Ozempic NAIONOpen Pharma | 3163 | 73+ | ~19 | FAST | Separate MDL created Dec 2025. NJ MCL active in parallel. |
Pharma | 3043 | ~3,025 | ~25 | FILING | Seeger Weiss, Wisner Baum active. |
Tech | 3171 | ~170 | ~20 | FAST | Rapid intake continues. |
Tech | 3084 | 2,075+ | ~15 | FILING | Slater Slater Schulman active. |
Cartiva SCIOpen Device | 3172 | ~400 | ~10 | FILING | Mediation ongoing. Bellwether May 26. |
Dupixent CTCLOpen Pharma | 3180 | 18+ | ~5 | FAST | JPML MDL motion filed. Ruling expected soon. |
Nitrous OxideOpen Consumer | Pre-MDL | ~325 | ~25 | FAST | Pre-MDL. Multiple firms active. |
FreeStyle LibreOpen Device | Pre-MDL | ~215 | ~15 | FILING | Seeger Weiss, Weitz & Luxenberg active. |
1,4-DioxaneOpen Chemical | E.D.N.Y | 30+ | ~3 | FILING | Weitz & Luxenberg, Napoli Shkolnik active. |
ByHeart FormulaOpen Consumer | Pre-MDL | ~22 | ~4 | FILING | JPML Birmingham hearing Mar 26. Ruling imminent. |
Chemical | 2741 | 4,200+ | ~15 | ACTIVE | Bayer settlement ongoing. New cases still filing. |
Chemical | E.D.N.C. | 95,000+ | ~200 | FILING | PACT Act claims. Federal government defendant. |
Zantac / RanitidineClosed Pharma | 2924 | 2,100+ | ~2 | FLAT | Most claims dismissed. Science rulings unfavorable. |
ParaquatOpen Chemical | 3004 | 5,400+ | ~35 | FILING | Parkinson's disease link. Syngenta/Chevron defendants. |
Consumer | Pre-MDL | ~500 | ~20 | FAST | Emerging ovarian cancer claims separate from J&J. |
NEC Baby FormulaOpen Consumer | 3026 | 1,800+ | ~12 | ACTIVE | Abbott/Mead Johnson. Premature infant NEC claims. |
Pharma | 3043 | ~3,025 | ~25 | FILING | Autism/ADHD link. Retailers as defendants. |
TepezzaOpen Pharma | Pre-MDL | ~200 | ~10 | FAST | Hearing loss side effect. Horizon Therapeutics. |
Philips CPAPOpen Device | 3014 | 750+ | ~8 | ACTIVE | Foam degradation. Cancer risk claims. |
ElmironBorderline Pharma | 2973 | 1,200+ | ~3 | FLAT | Vision damage. Settlement discussions ongoing. |
Exactech ImplantOpen Device | 3044 | 900+ | ~10 | FILING | Polyethylene insert failures. |
BelviqOpen Pharma | Pre-MDL | ~150 | ~8 | FAST | Cancer risk. Pulled from market 2020. |
Chemical | Pre-MDL | ~400 | ~15 | FAST | PFAS exposure. Emerging litigation. |
Toxic Baby FoodOpen Consumer | Pre-MDL | ~300 | ~10 | FILING | Heavy metals in baby food. Multiple defendants. |
FluoroquinoloneBorderline Pharma | Pre-MDL | ~250 | ~2 | FLAT | Cipro/Levaquin. Peripheral neuropathy. |
Proton Pump InhibitorsClosed Pharma | 2789 | 12,000+ | ~5 | FLAT | Nexium/Prilosec. Kidney damage. Mostly settled. |
IVC FilterClosed Device | 2641 | 3,800+ | ~3 | FLAT | Bard/Cook. Filter migration/fracture. |
RisperdalClosed Pharma | 2767 | 900+ | ~2 | FLAT | Gynecomastia. Most cases resolved. |
3M EarplugsClosed Device | 2885 | Settled | 0 | FLAT | $6B settlement complete. Monitoring ongoing. |
ValsartanClosed Pharma | 2875 | 1,400+ | ~3 | FLAT | NDMA contamination. Cancer claims. |
Consumer | 3038 | 4,500+ | ~15 | ACTIVE | Youth vaping. School district claims. |
Other | Pre-MDL | ~50 | ~3 | FAST | Antitrust. PGA merger implications. |
Tech | Pre-MDL | ~100 | ~5 | FILING | Driver-on-passenger assault claims. |
WeChat PrivacyOpen Tech | Pre-MDL | ~75 | ~4 | FAST | Data privacy violations. CCPA claims. |
Monsanto PCBOpen Chemical | 2342 | 2,500+ | ~10 | FILING | Environmental contamination. School claims. |
Consumer | 2738 | Part of Talc | ~20 | FILING | Subset of Talc MDL. |
Pharma | Pre-MDL | ~100 | ~5 | FAST | Autoimmune injury claims. Merck defendant. |
Metal-on-Metal HipClosed Device | 2244 | 4,000+ | ~2 | FLAT | DePuy/Stryker. Mostly resolved. |
Pharma | Pre-MDL | ~50 | ~3 | FAST | Immune-related organ failure. Merck defendant. |
Critical Dates — Next 60 Days
6 events| Date | Docket | Event | Investor Significance |
|---|---|---|---|
| Jun 10, 2026 | Suboxone MDL 3092 | 20-case Core Discovery Pool random selection | Picks the cases that drive bellwether settlement values |
| Jun 10, 2026 | Hair Relaxer MDL 3060 | Bellwether fact discovery cutoff (Judge Rowland) | Discovery close gates summary judgment timing for 2027 trials |
| Jun 15, 2026 | Social Media MDL 3047 | Federal bellwether trial begins | Landmark federal trial; massive settlement implications |
| Jun 24, 2026 | Depo-Provera MDL 3140 | Daubert / general causation hearing begins (3 days) | Outcome controls whether MDL survives — make-or-break for Pfizer |
| Jun 26, 2026 | Depo-Provera MDL 3140 | Case management conference (N.D. Fla.) | Post-Daubert CMC will recalibrate bellwether trial dates |
| Jul 2, 2026 | Suboxone MDL 3092 | Parties identify 15 preferred representative cases | Each side's picks signal trial-ready injury profiles |
New Filings — May 26 – Jun 8, 2026
| Case | Defendant | Court | Theory | Lead Firm |
|---|---|---|---|---|
| Rodriguez v. Meta Platforms | Meta Platforms, Inc. | N.D. Cal. | Product liability — algorithmic addiction | Motley Rice LLC |
| Thompson v. Bard Medical | Bard Medical / BD | D. Ariz. | Device failure — catheter fracture | Levin Papantonio |
| Williams v. Pfizer Inc. | Pfizer Inc. | S.D.N.Y. | Failure to warn — Depo-Provera meningioma | Wisner Baum |
| Garcia v. Novo Nordisk | Novo Nordisk A/S | E.D. Pa. | GLP-1 gastroparesis / bowel obstruction | Beasley Allen |
| Davis v. Lyft, Inc. | Lyft, Inc. | N.D. Cal. | Negligent hiring — sexual assault | Slater Slater Schulman |
| Chen v. Abbott Labs | Abbott Laboratories | N.D. Ill. | Device defect — FreeStyle Libre burns | Seeger Weiss LLP |
Analyst Notes & Portfolio Strategy
Priority assessments, stage analysis, and portfolio positioning across active mass tort dockets.
Analyst Notes — Investor Outlook
Social Media Youth Addiction
Elevated PriorityThe NM verdict fundamentally shifts the litigation landscape. Federal bellwether on June 15 is the next major catalyst. Expect heightened settlement pressure on Meta/Google. Monitor appellate timeline closely — a sustained verdict dramatically increases portfolio exposure.
Talc / J&J
Bankruptcy WatchThird prepackaged bankruptcy attempt (June 2 hearing) remains the central variable. CA verdict vacation adds complexity. Resolution of 67K+ claims hinges on bankruptcy court approval of $8.9B trust proposal.
Hair Relaxer
Trial PreparationBellwether selections signal active progression. Three cases chosen April 1 will define trial strategy. L'Oreal, Revlon exposure significant. Watch for Daubert rulings on causation experts in coming weeks.
Depo-Provera
Elevated PriorityPreemption ruling (expected May 5) is threshold issue. If denied, rapid case growth likely accelerates. Pfizer exposure could be substantial given long market history and meningioma causation evidence.
Ozempic / GLP-1
Critical JunctureMay 12 Daubert hearing is make-or-break. Favorable ruling opens massive liability exposure for Novo Nordisk and Eli Lilly. Unfavorable ruling could significantly deflate docket. High-stakes binary outcome.
Bard PowerPort
Trial ImminentCook Medical bellwether (April 21) is the first catheter port trial. Outcome will set settlement benchmarks. BD/Bard cases to follow. Device failure evidence is strong — favorable plaintiff verdict expected.
Opportunities by Stage
Early signals. Pre-MDL formation. First-mover window.
Active investigation. Firms building inventory.
Meaningful case volume. Bellwethers approaching.
Multi-front mass tort. Settlement pressure.
The Diversified Core Portfolio
8 curated mass tort positions across 5 sectors and 4 stages.
Don't miss a ruling, verdict, or filing.
Every Monday: critical docket developments, filing velocity changes, bellwether outcomes, and portfolio signals — in one email.
Upload expert documents into the live docket board
Upload litigation reports, filings, or normalized JSON. Trusted docket facts become homepage overrides when they match a live MDL or tracked docket.